MedTrace Logo

Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer

NCT02711865 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2016-03-17

No results posted yet for this study

Summary

The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.

Conditions

Interventions

BIOLOGICAL

IGF1R antibody MK0646

OTHER

Saline solution

Sponsors & Collaborators

  • Hillel Yaffe Medical Center

    lead OTHER_GOV

Principal Investigators

  • Ilan Bruchim, MD · Hillel Yaffe Medical Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-05-31
Completion
2019-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02711865 on ClinicalTrials.gov